The strength of F-star’s Modular Antibody Technology and mAb² programs have been leveraged through partnerships with leading biopharmaceutical companies within immuno-oncology and beyond.

	2020: Merck KGaA, Darmstadt, Germany Takes an Early Option in Immuno-Oncology Collaboration   2019: F-star expedites its transition to a wholly-owned portfolio strategy   2017: F-star Expands its Relationship with Merck through a new Strategic Collaboration to Develop Bispecific Antibodies in Immuno-Oncology   2011: Joint discovery and development of new antibody-derived therapeutic products
	2018: F-star Announces Early Exercise by Denali Therapeutics of its Option to Acquire F-star Gamma   2016: F-star Announces Collaborative Agreement with Denali Therapeutics for the Development of a Multispecific Antibody Platform to Deliver Therapeutics Across the Blood-Brain Barrier